[Edaily Reporter Kwon Oh-seok] L&C Bio, a company specializing in human tissue regenerative medicine, announced on the 12th that it has been newly included in the KRX300 index as part of the Korea Exchange (KRX)’s regular index review.

The KRX300 is a representative index comprising 300 stocks selected from the Korea Exchange (KOSPI) and KOSDAQ markets that meet criteria such as high market capitalization, liquidity, financial soundness, and market representativeness. It is widely used as a benchmark by pension funds and institutional investors for asset management, and there is a significant amount of passive capital tracking this index.
The company explained that this inclusion is highly significant as it represents official recognition of L&C Bio’s business competitiveness, growth potential, and market visibility. In particular, the company anticipates that being included in the list of eligible stocks for KRX300-tracking funds and institutional investors will lead to increased trading activity and an expanded investment base in the future.
L&C Bio is a regenerative medicine platform company based on human tissue-derived extracellular matrix (ECM), boasting a diverse portfolio that includes the surgical product “Rituo,” as well as Megaderm, Meganeur, and Megacarti. Recently, as the skin regeneration and aesthetics market—which had previously centered on fillers—shifts its focus toward fundamental tissue regeneration solutions based on ECM, the company is rapidly enhancing its related technological capabilities and product competitiveness.
Leveraging these strengths, the company is also accelerating its expansion into overseas markets, including Southeast Asia and North America. An L&C Bio official stated, “Inclusion in the KRX300 index demonstrates not only the company’s growth potential but also market confidence,” adding, “We will simultaneously enhance corporate value and shareholder value through continuous R&D and global business expansion centered on our skin booster ‘Litwo.’”